A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation

PACE - Pacing and Clinical Electrophysiology

Volumn 36, Issue 2, 2013, Pages 172-179

  Nin, Takamitsu ^a   Sairaku, Akinori ^a,b   Yoshida, Yukihiko ^a   Kamiya, Hiroki ^a   Tatematsu, Yasushi ^a   Nanasato, Mamoru ^a   Inden, Yasuya ^c   Hirayama, Haruo ^a   Murohara, Toyoaki ^c  

^a NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

Author keywords

ablation; atrial fibrillation; D dimer; dabigatran; periablation anticoagulation; rebleeding; time to ablation

Indexed keywords

D DIMER; DABIGATRAN; HEPARIN; PROTON PUMP INHIBITOR; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CARDIAC PATIENT; CATHETER ABLATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HEART ATRIUM FIBRILLATION; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MESENTERIC ARTERY; RANDOMIZED CONTROLLED TRIAL; THROMBECTOMY; TREATMENT DURATION; TREATMENT OUTCOME; VEIN PUNCTURE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIOPERATIVE CARE; PREMEDICATION; THROMBOSIS; TREATMENT OUTCOME; WARFARIN;

EID: 84873376913     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/pace.12036     Document Type: Article

References (21)

1. Turpie AG,. New oral anticoagulants in atrial fibrillation. Eur Heart J 2008; 29: 155-165.
2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
3. Lakkireddy D, Reddy YM, Di Biase L, Vanga SR, Santangeli P, Swarup V, Pimentel R, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: Results from a multicenter prospective registry. J Am Coll Cardiol 2012; 59: 1168-1174.
4. Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA,. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol 2012; 23: 264-268.
5. Dagres N, Hindricks G, Kottkamp H, Sommer P, Gaspar T, Bode K, Arya A, et al. Complications of atrial fibrillation ablation in a high-volume center in 1,000 procedures: Still cause for concern? J Cardiovasc Electrophysiol 2009; 20: 1014-1019.
6. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010; 3: 32-38.
7. Sairaku A, Nakano Y, Oda N, Makita Y, Kajihara K, Tokuyama T, Kihara Y,. Rapid hemostasis at the femoral venous access site using a novel hemostatic pad containing kaolin after atrial fibrillation ablation. J Interv Card Electrophysiol 2011; 31: 157-164.
8. Lee DS, Dorian P, Downar E, Burns M, Yeo EL, Gold WL, Paquette M, et al. Thrombogenicity of radiofrequency ablation procedures: What factors influence thrombin generation ? Europace 2001; 3: 195-200.
9. Bulava A, Slavík L, Fiala M, Heinc P, Skvarilova M, Lukl J, Krcová V, et al. Endothelial damage and activation of the hemostatic system during radiofrequency catheter isolation of pulmonary veins. J Interv Card Electrophysiol 2004; 10: 271-279.
10. Gage BF,. Can we rely on RE-LY? N Engl J Med 2009; 361: 1200-1202.
11. J-RHYTHM Registry Investigators. Determinants of warfarin use and international normalized ratio levels in atrial fibrillation patients in Japan. Subanalysis of the J-RHYTHM Registry. Circ J 2011; 75: 2357-2362.
12. Ouyang F, Bänsch D, Ernst S, Schaumann A, Hachiya H, Chen M, Chun J, et al. Complete isolation of left atrium surrounding the pulmonary veins: New insights from the double-Lasso technique in paroxysmal atrial fibrillation. Circulation 2004; 110: 2090-2096.
13. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: Recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm 2012; 14: 528-606.
14. Habara S, Dote K, Kato M, Sasaki S, Goto K, Takemoto H, Hasegawa D, et al. Prediction of left atrial appendage thrombi in non-valvular atrial fibrillation. Eur Heart J 2007; 28: 2217-2222.
15. Sadanaga T, Sadanaga M, Ogawa S,. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. J Am Coll Cardiol 2010; 55: 2225-2231.
16. Moreyra E, Finkelhor RS, Cebul RD,. Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: An analysis of pooled trials. Am Heart J 1995; 129: 71-75.
17. Hirsh J, Fuster V, Ansell J, Halperin JL,. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003; 107: 1692-1711.
18. Green L, Lawrie AS, Patel R, Stephens RC, Mackie IJ, Chitolie A, Haddad FS, et al. The effect of total hip/knee replacement surgery and prophylactic dabigatran on thrombin generation and coagulation parameters. Thromb Res 2012 (in press).
19. Oral H, Chugh A, Ozaydin M, Good E, Fortino J, Sankaran S, Reich S, et al. Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation 2006; 114: 759-765.
20. du Breuil AL, Umland EM,. Outpatient management of anticoagulation therapy. Am Fam Physician 2007; 75: 1031-1042.
21. Yamaguchi T,. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: A multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke 2000; 31: 817-821.